Type 2 diabetes and obesity

Tirzepatide improves glucose control more than semaglutide in people with type 2 diabetes by improving beta-cell function as well as boosting insulin sensitivity and reducing glucagon secretion, shows a randomized trial.

The publication of two SURPASS-3 substudies in The Lancet Diabetes & Endocrinology reveals significant benefits of tirzepatide on liver and abdominal fat in people with type 2 diabetes, as well as on time in target glucose range.

People are much more likely to achieve lasting type 2 diabetes remission with surgical rather than medical intervention, even if they have only mild obesity, shows 3-year follow-up of four randomized trials.

Real-world data confirm glycated hemoglobin and weight benefits, albeit attenuated, for people with type 2 diabetes switching to injectable semaglutide from other GLP-1 receptor agonists.

Type 2 diabetes in young, lean people is much more common in Asian Indians than in White Europeans, say researchers who found that genetically determined beta-cell function may be to blame.

The gain or loss of more than 5% bodyweight within a 2-year period is associated with an increased risk for major adverse cardiovascular events in people with type 2 diabetes, say researchers.

People with obesity, particularly when diagnosed before the age of 50 years, are at very high risk for developing multiple comorbid conditions, say researchers.

Only a third of people given a glucagon-like peptide-1 receptor agonist in clinical practice lose a clinically meaningful amount of weight, potentially due to high rates of discontinuation, say researchers.

People in different type 2 diabetes subgroups may experience varying levels of improvement after bariatric surgery, with those in the severe insulin-resistant diabetes group most likely to benefit, study findings indicate.

The STEP 6 findings reveal significant weight loss, along with a reduction in abdominal visceral fat, in east Asian people with obesity taking a high dose of semaglutide.

BMI has a strong positive linear association with type 2 diabetes risk that generally does not vary by global region or ethnicity, show results of a dose-response meta-analysis.

Findings from the prospective Swedish Obese Subjects study suggest that bariatric surgery in people with concomitant type 2 diabetes and obesity is linked to a lower cancer incidence than conventional obesity treatment.

Higher BMI, waist circumference, and fat mass are each significantly associated with an increased risk for heart failure among older people with diabetes but not among those without diabetes, US researchers report.

Gastric bypass and sleeve gastrectomy both result in “almost complete clearance of liver fat” within a year after the intervention, show secondary outcomes of a randomized trial.

Researchers have found evidence that almost one in 20 people diagnosed with type 2 diabetes in routine clinical care later achieve remission.

Tirzepatide provides better glucose control than insulin glargine in people with type 2 diabetes taking multiple oral antidiabetes medications, report the SURPASS-4 investigators in The Lancet.

Many participants of DiRECT found reintroduction of food and subsequent weight-loss maintenance to be more challenging than the 800 calorie total meal replacement phase, the investigators report.

Semaglutide treatment results in significant reductions in levels of the inflammatory marker high-sensitivity C-reactive protein, indicates further analysis of the PIONEER and SUSTAIN trials.

Findings from the SoliMix trial indicate that iGlarLixi may improve glycemic control with weight benefit compared with BIAsp 30 among people with suboptimally controlled type 2 diabetes on basal insulin.

Outwardly lean people who have type 2 diabetes have increased intra-organ fat, reductions in which occur in line with weight loss-induced diabetes remission, say researchers.